Publications by authors named "Christopher Banfield"

Claim this Profile
A
Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primates.
Song Eun Lee, Hind Bouzid, Cheryl Kwan, Ajay Sharma, Andrea R Romo, Christopher Banfield

J Allergy Clin Immunol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
David Fiorentino, Aaron R Mangold, Victoria P Werth, Lisa Christopher-Stine, Alisa Femia, Christopher Banfield

Lancet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.
Mina Hassan-Zahraee, Zhan Ye, Li Xi, Elizabeth Dushin, Julie Lee, Christopher Banfield

J Crohns Colitis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis.
Jessica Wojciechowski, Arnab Mukherjee, Christopher Banfield, Timothy Nicholas

Clin Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans.
Jonathan N Bauman, Angela C Doran, Gabrielle M Gualtieri, Brian Hee, Timothy Strelevitz, Christopher Banfield

Drug Metab Dispos· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis.
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield

J Pharmacokinet Pharmacodyn· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development.
Elena Peeva, Anindita Banerjee, Christopher Banfield, Koshika Soma, Jared Christensen

Drug Discov Today· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno-inflammatory diseases.
Farzaneh Maleki, Elias Clark, Christopher Banfield, Wonkyung Byon, Timothy Nicholas

CPT Pharmacometrics Syst Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
Alexa B Kimball, Elena Peeva, Seth Forman, Ali Moiin, Saakshi Khattri, Christopher Banfield

NEJM Evid· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Study of Dermal Pharmacokinetics Between Topical Drugs Using Open Flow Microperfusion in a Pig Model.
Manfred Bodenlenz, Thean Yeoh, Gabriel Berstein, Shibin Mathew, Jaymin Shah, Christopher Banfield

Pharm Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Comparative Study of Dermal Pharmacokinetics Between Topical Drugs Using Open Flow Microperfusion in a Pig Model.
Manfred Bodenlenz, Thean Yeoh, Gabriel Berstein, Shibin Mathew, Jaymin Shah, Christopher Banfield

Pharm Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development.
Jessica Wojciechowski, Vivek S Purohit, Yeamin Huh, Christopher Banfield, Timothy Nicholas

Clin Pharmacokinet· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a C-microdose approach.
Ruolun Qiu, Raman Sharma, Hua Wei, Leonid Kirkovsky, Yifan Zhou, Christopher Banfield

Br J Clin Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
William J Sandborn, Silvio Danese, Jaroslaw Leszczyszyn, Jacek Romatowski, Engin Altintas, Christopher Banfield

Clin Gastroenterol Hepatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Megan N Landis, Stacy R Smith, Gabriel Berstein, Gerald Fetterly, Pranab Ghosh, Christopher Banfield

Br J Dermatol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Megan N Landis, Mark Arya, Stacy Smith, Zoe Draelos, Lisa Usdan, Christopher Banfield

Br J Dermatol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients.
Jim H Hughes, Ruolun Qiu, Christopher Banfield, Martin E Dowty, Timothy Nicholas

Clin Pharmacol Drug Dev· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Jonathan N Bauman, Angela C Doran, Amanda King-Ahmad, Raman Sharma, Gregory S Walker, Christopher Banfield

Drug Metab Dispos· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Emma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, Ning Zhang, Ester Del Duca, Christopher Banfield

J Allergy Clin Immunol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.
Silvio Danese, Maria Klopocka, Ellen J Scherl, Jacek Romatowski, Jessica R Allegretti, Christopher Banfield

Clin Gastroenterol Hepatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
Brett King, Emma Guttman-Yassky, Elena Peeva, Anindita Banerjee, Rodney Sinclair, Christopher Banfield

J Am Acad Dermatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Michael F Robinson, Nemanja Damjanov, Bojana Stamenkovic, Goran Radunovic, Alan Kivitz, Christopher Banfield

Arthritis Rheumatol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib.
Elena Soto, Christopher Banfield, Pankaj Gupta, Mark C Peterson

CPT Pharmacometrics Syst Pharmacol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Karen M Page, Mayte Suarez-Farinas, Maria Suprun, Weidong Zhang, Sandra Garcet, Christopher Banfield

J Invest Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
Christopher Banfield, Dan Rudin, Indranil Bhattacharya, Kosalaram Goteti, Gang Li

Br J Clin Pharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis